Group 1 - The core viewpoint of the articles highlights the rapid rise of recombinant collagen in the medical beauty and skincare industry, challenging the dominance of hyaluronic acid [1][2][16] - Jinjian Biological's stock price has surged over 100% since the beginning of the year, reaching a historical high of 442.00 yuan per share, with a listing price of 49 yuan per share in 2023 [1] - The founder of Jinjian Biological, Yang Xia, has seen a significant increase in wealth, ranking 2295th on the Hurun Global Rich List with a net worth of approximately 11.5 billion yuan, up 455 places year-on-year [1] Group 2 - The wealth of founders in the hyaluronic acid sector, such as Zhao Yan of Huaxi Biological and Jian Jun of Aimeike, has declined, indicating a shift in the industry landscape [2] - Huaxi Biological reported a revenue of 5.371 billion yuan in 2024, a year-on-year decrease of 11.61%, and a net profit decline of 70.59% [19] - Aimeike's revenue for 2024 was 3.026 billion yuan, with a slight growth of 5.45%, but faced a decline in net profit [19] Group 3 - Jinjian Biological's revenue for 2024 reached 1.443 billion yuan, a year-on-year increase of 84.92%, with a net profit of 732 million yuan, up 144.27% [6] - The company achieved a gross margin of 95.03% in its medical device segment, surpassing the gross margin of Kweichow Moutai [7] - Jinjian Biological's focus on medical devices and functional skincare products has positioned it as a strong competitor in the market [6][14] Group 4 - The competitive landscape is shifting, with Jinjian Biological and Juzhi Biological both expanding into medical beauty injections, potentially leading to direct competition [13][17] - Jinjian Biological has received approval for its injectable recombinant collagen gel, indicating ongoing product development and market expansion [14] - The industry is witnessing a trend towards international expansion, with companies like Jinjian Biological and Huaxi Biological exploring overseas markets [24][25] Group 5 - The financial performance of Chuangjian Medical has declined, with a revenue of 288.2 million yuan in 2024, a growth of only 1.82%, and a net profit drop of 50.84% [6][15] - Chuangjian Medical is attempting to pivot towards terminal products, including medical devices and cosmetics, but lacks strong competitive advantages [14][15] - The overall market for recombinant collagen is still in its early stages of international expansion, with companies planning to enhance their global presence [25]

合成生物学因其具有的革命性和颠覆性创新潜力，已成为世界各国抢占的新科技战略热点。目前，全球 已有 50 多个国家和地区发布合成生物学相关战略部署和支持计划，纷纷通过 加大投入、完善设施、创 新监管 等具体举措，加快抢占未来经济发展制高点。中国凭借完整的产业链优势与政策红利，有望在 合成生物驱动的"新质生产力"浪潮中占据引领地位，进一步释放合成生物在成分定制、资源节约和低碳 转型中的潜力，成为全球生物经济的重要增长极。 2025第二届合成生物制造创新发展大会 将于 2025年5月22-23日 在 上海浦东喜来登由由大酒店 盛大启 幕。本次大会以" 合成新'基'遇，智造赢未来 "为主题，邀请 全球生物制造领域的专家、企业家 和科研 机构 ，聚焦合成生物技术在 医药、食品、化妆品、新材料、AI方向 的应用，共同探讨生物制造技术的 发展趋势、市场机遇与挑战，为全球消费者提供更安全、高效、可持续的创新解决方案。 0元门票限时领取中 邀您直达新质生产力前沿！ 组织架构 ▶ 指导单位： 上海市经济和信息化委员会、上海市浦东新区科技和经济委员会 ▶ 主办单位： 中国医药保健品进出口商会、上海市合成生物产业协会、上海博华国际展 ...

2 0 2 4年在国货美妆发展史上是值得记录一年： 一方面，国内诞生首个突破百亿美妆企业，珀莱雅以1 0 7 . 7 8亿元营收首次跻身"百亿俱乐部"， 成 为 行 业 里 程 碑 事 件 ； 同 时 ， 十 强 门 槛 抬 高 至 近 3 0 亿 元 ， 前 十 总 营 收 规 模 扩 大 至 5 4 3 . 7 7 亿 元。 另一方面，前十座次发生较大变化，毛戈平首次闯入榜单，上海家化、华熙生物等企业持续步 入变革期深水区，迎来业绩"震荡"。 在"突飞猛进"与震荡调整并存的阶段，头部国货企业的发展预示着行业怎样的未来？ 综 合 2 0 2 1 年 至 2 0 2 4 年 国 货 美 妆 上 市 企 业 十 强 榜 单 情 况 来 看 ， 可 以 发 现 ， 名 次 发 生 了 较 大 变 化。每一年的前三名都不相同，并且持续有"突围者"闯入榜单，例如2 0 2 4年的毛戈平。 | | | | 2021年至2024年国货美妆上市企业十强榜单 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | -- ...

Group 1 - The core viewpoint of the news highlights significant growth in the Hang Seng Medical Index ETF, with a turnover of 8.66% and a transaction volume of 22.28 million yuan, indicating strong liquidity [2] - The Hang Seng Medical Index ETF has seen a scale increase of 21.32 million yuan over the past two weeks, reflecting substantial growth [2] - The ETF's shares have increased by 10 million shares this month, demonstrating notable growth in share volume [2] Group 2 - The latest price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 24.59 times, which is at a historical low, being in the 6.16% percentile over the past year, indicating undervaluation [2] - A recent policy initiative by seven government departments aims to enhance the digital transformation of the pharmaceutical industry by 2027, focusing on improving competitiveness and quality management across the entire industry chain [2] - CITIC Securities suggests that the policy will guide digital innovation in the pharmaceutical industry, with expectations for a comprehensive data system and innovation ecosystem by 2030, thus creating investment opportunities in the healthcare sector [2] Group 3 - As of April 29, 2025, the top ten weighted stocks in the Hang Seng Medical Index include WuXi Biologics, BeiGene, Innovent Biologics, and others, collectively accounting for 57.26% of the index [3] - Investors without stock accounts can access the Hong Kong medical sector investment opportunities through the Hang Seng Medical Index ETF linked fund (018433) [3]

Core Viewpoint - The performance of beauty companies listed in 2024 reflects a challenging environment, with many traditional giants facing significant losses while some emerging brands show strong growth [1][2]. Industry Overview - In 2024, China's total retail sales of consumer goods grew by 3.5%, but the retail sales of cosmetics declined by 1.1%, amounting to 435.65 billion yuan [2]. - The overall industry is experiencing a downturn, leading to price cuts and store closures by several foreign brands [2]. - Major companies like Shanghai Jahwa reported a loss of 833 million yuan, highlighting the struggles of established players [2][4]. Company Performance - As of April 27, 2024, 15 A-share cosmetic companies reported a total revenue of 50.081 billion yuan, a year-on-year increase of 3.59%, but net profit fell to 3.765 billion yuan, down from 5.127 billion yuan [4]. - Notable performances include: - Proya achieved revenue of 10.778 billion yuan, becoming the first domestic beauty brand to surpass 10 billion yuan [2][11]. - Shanghai Jahwa's revenue decreased by 13.93% to 5.679 billion yuan, with a net profit loss of 833 million yuan [6]. - Betaini reported revenue of 5.736 billion yuan, up 3.87%, but net profit fell by 33.53% to 503 million yuan [8]. - Huaxi Biological's revenue dropped by 11.61% to 5.371 billion yuan, with net profit down 70.59% to 174 million yuan [8]. Emerging Brands - New entrants like Gu Yu Biotechnology are preparing to enter the capital market, showcasing strong growth with a revenue of 4 billion yuan and GMV exceeding 5 billion yuan [14][15]. - Gu Yu's success is attributed to its focus on a unique ingredient and effective online marketing strategies, although its reliance on a single product category may pose future challenges [15]. Market Trends - The market is witnessing a shift where traditional giants are retracting while new players are emerging, indicating a potential reshaping of the industry landscape [10][14]. - The global beauty market is expected to see a coexistence of domestic brands leading in niche segments while foreign brands focus on high-end markets [16].

Investment Rating - The report maintains an "Outperform" rating for the social services industry [1][27]. Core Insights - The report emphasizes the importance of expanding service consumption and highlights that new consumption continues to attract funding [1][3]. - The macroeconomic environment is supportive of service consumption growth, with government policies aimed at increasing income for low- and middle-income groups and enhancing consumption's role in economic growth [4][5]. - The report notes that service consumption has a high frequency of transactions, strong multiplier effects, and sustainable growth potential, with significant contributions to overall consumer spending [5]. Summary by Sections Macroeconomic and Industry Dynamics - The Politburo meeting on April 25 discussed the current economic situation, emphasizing support for technology innovation, consumption expansion, and stable foreign trade [3][4]. - The State Taxation Administration revised the management measures for tax refunds for overseas travelers, facilitating easier tax refund processes [4]. - Recent reports highlight the importance of service consumption as a key driver for domestic demand, with a projected 6.2% growth in service retail sales in 2024, outpacing goods retail sales [5]. Company Dynamics - Traditional retail continues to optimize, with companies like Yonghui Supermarket successfully launching products through green channels for foreign trade [6][7]. - Beauty industry companies reported strong financial performances, with Jinbo Bio achieving a 62.51% year-on-year revenue increase in Q1 2025 [3][13]. - The report highlights the performance of various companies, including a significant turnaround for Bubugao, which reported a 164.16% increase in net profit in 2024 [7][14]. Investment Recommendations - The report notes that the social services sector has seen a rotation in performance, with key companies trading at a PE ratio of 20-40 times for 2025, indicating stable operations and solid growth potential [3][27]. - The report suggests that the market is favoring high-growth companies within the social services sector, with significant year-to-date increases in stock prices for companies like Shangmei and Maogeping [24][27].

东吴证券研报对新消费的特点进行了深入剖析。新消费具有"人传人""可交易""易造梗"等独特特点。与 传统消费不同，新消费的消费习惯、产品以及品牌具备"人传人"的传播性。其最终目的是让用户成为营 销官，不再依赖公司投放广告，而是让用户主动进行营销。同时，股东也会积极参与营销，形成一 个"圈层群体"的整体营销模式。 新消费相关港股企业包括： 泡泡玛特（09992）、老铺黄金（06181)、毛戈平（01318）、蜜雪集团（02097）、布鲁可（00325）、 古茗（01364）、奈雪的茶（02150）、巨子生物（02367）等。 智通财经APP获悉，随着年轻一代消费观念的转变和消费市场的不断升级，新消费有望在未来持续释放 巨大的发展潜力，成为推动经济增长的重要力量。 申万菱信乐融一年持有混合基金付娟表示，不同于过去依靠人口红利的旧周期，这一轮的消费新周期或 会呈现一个长周期的走势，其根植于年轻化的人口代际的变化。他们更加重视内心的愉悦，有着相对较 高的付费意愿，更加积极拥抱新的科技水平，也面临更加充足的产品供给。 券商普遍认为，在提振内需、促进消费的明确方向下，消费政策预期持续受到关注，目前市场预期升温 已有所体现， ...

Core Viewpoint - The healthcare sector is experiencing a strong upward trend, with significant growth in key companies and ETFs, particularly driven by the performance of WuXi AppTec and the overall positive market sentiment towards innovative pharmaceuticals [3][4]. Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) rose by 1.54%, with notable increases in stocks such as WuXi AppTec (up 4.98%) and Kelun-Biotech (up 4.17%) [3]. - The Hang Seng Healthcare ETF (513060) increased by 1.26%, with a latest price of 0.48 yuan and a turnover rate of 2.11%, amounting to a transaction volume of 226 million yuan [3]. - Over the past month, the average daily trading volume of the Hang Seng Healthcare ETF reached 1.986 billion yuan, ranking first among comparable funds [3]. Group 2: Company Financials - WuXi AppTec reported a strong Q1 performance with revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, up 89.06% [3]. - This marks the first time since Q4 2022 that WuXi AppTec achieved double-digit growth in both revenue and net profit [3]. Group 3: ETF Performance and Metrics - The Hang Seng Healthcare ETF has a current scale of 10.648 billion yuan, ranking in the top third among comparable funds [4]. - The ETF's net value increased by 32.62% over the past year, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 1.73, indicating strong risk-adjusted returns [5][6]. Group 4: Valuation and Holdings - The Hang Seng Healthcare Index has a current price-to-earnings ratio (PE-TTM) of 24.1, which is below 95.29% of the historical data over the past year, indicating a low valuation [6]. - The top ten weighted stocks in the index account for 57.31% of the total, with significant contributions from companies like WuXi Biologics and BeiGene [6][8].

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the new consumption sectors, specifically focusing on the beauty and trendy toy industries, highlighting the impact of Generation Z on consumer behavior and market dynamics [1][2][3]. Core Insights and Arguments Beauty Industry - The beauty industry is benefiting from the logic of domestic product substitution, with domestic brands continuously increasing their market share, particularly in the mid-to-high-end market [1][2][5]. - The market for skincare products, especially eye and facial care, is growing significantly faster than the overall market, driven by emerging functional ingredients like recombinant collagen and signaling molecules [1][15]. - The beauty sector is experiencing a shift from traditional e-commerce to content-driven e-commerce, necessitating changes in marketing strategies and organizational structures to adapt to a "product finds people" model [1][3][4]. - The impact of the US-China tariff war has made domestic beauty products more attractive, with over 10 billion yuan worth of beauty products imported from the US facing tariffs, enhancing the competitiveness of local brands [2][5]. - Companies like Proya, Betaini, and Perfect Diary are expected to show strong performance despite facing profit pressures, indicating overall strengthening competitiveness in the sector [2][5]. Trendy Toy Industry - The trendy toy industry is heavily reliant on IP (intellectual property) comprehensive operation capabilities rather than manufacturing, with leading companies maintaining competitive advantages through design and supply chain innovations [1][30][31]. - The market for trendy toys is rapidly growing, with a 30% year-on-year increase in the domestic pan-entertainment toy market, expected to maintain a compound annual growth rate of 14% over the next five years [31]. - Companies like Pop Mart are expanding their market presence in Southeast Asia and the US, with revenue growth expected to exceed market expectations [1][30][40]. Additional Important Insights - The beauty industry is transitioning from an incremental market logic to a stock market logic, with new business models and companies emerging [5][6]. - The rise of Generation Z as a primary consumer group is driving demand for products that emphasize emotional and personal expression, leading to structural opportunities in niche markets like trendy toys and beauty care [1][3][8]. - The beauty sector is seeing a shift towards personalized marketing and decentralized promotion strategies, reflecting changes in consumer preferences and shopping behaviors [4][11]. - The competitive landscape in the trendy toy sector is evolving, with leading brands like Pop Mart and others leveraging their IP capabilities to capture market share from smaller players [30][35][36]. Conclusion - The beauty and trendy toy industries are undergoing significant transformations driven by changing consumer preferences, competitive dynamics, and macroeconomic factors. The focus on domestic brands, innovative marketing strategies, and IP management will be crucial for companies looking to capitalize on these trends in the coming years [1][5][30][31].

Financial Performance - Revenue for 2024 reached RMB 5,538.8 million, a 57.2% increase from RMB 3,524.1 million in 2023[6] - Gross profit for 2024 was RMB 4,546.9 million, reflecting a 54.3% growth compared to RMB 2,947.1 million in 2023[6] - Net profit attributable to shareholders for 2024 was RMB 2,062.3 million, up 42.1% from RMB 1,451.8 million in 2023[6] - The company achieved a total revenue of RMB 55.39 billion, representing a year-on-year growth of 57.2%[11] - Adjusted net profit reached RMB 21.52 billion, with a year-on-year increase of 46.5%[11] - Total revenue for the year ended December 31, 2024, reached RMB 5,538.8 million, a 57.2% increase from RMB 3,524.1 million for the year ended December 31, 2023[31] - Direct sales revenue grew over 70% year-on-year in 2024, becoming a major driver of business growth[10] - Direct sales and distribution channels generated revenues of RMB 4,134.2 million and RMB 1,404.6 million, accounting for 74.6% and 25.4% of total revenue, respectively[26] - Professional skin care products accounted for 77.7% of total revenue in 2024, with RMB 4,302.3 million in sales, up from 75.1% and RMB 2,647.3 million in 2023[32] - Total sales cost for 2024 was RMB 991.9 million, a 71.9% increase from 2023, primarily due to increased sales volume and material costs[43] - Gross profit for 2024 was RMB 4,546.9 million, a 54.3% increase from 2023, with a gross margin of 82.1%, down from 83.6% in 2023[44] Research and Development - Research and development investment increased by 42% in 2024, with 74 new patents and applications filed[9] - Research and development expenditure amounted to RMB 106.5 million, a 42.1% increase year-on-year, accounting for 1.9% of total revenue[13] - The company has 188 ongoing research projects and holds 167 patents, with 74 new patents granted during the reporting period[13] - The company plans to increase R&D investment and prepare for the commercialization of three categories of medical devices by 2025[30] Market Expansion and Product Development - The company established a multi-brand development matrix, launching innovative products that gained consumer favor[10] - The company is actively expanding its international market presence, aiming to bring its products to global consumers[11] - The company is focusing on the development of innovative and competitive products to meet diverse consumer needs[11] - The "可復美" brand has developed a comprehensive product matrix, including a major medical device series and four skincare series, enhancing its market presence[16] - The company launched the new "Kefumei Focus Series" targeting skin conditions such as dullness and acute fatigue, with the "Kefumei Focus Cream" achieving top rankings in sales during the 2024 Double Eleven shopping festival[19] - The company expanded its product offerings with the "Kefumei Order Series" and "Kefumei Ton Ton Series," addressing various consumer needs and enhancing brand reach[20] Sales and Distribution Channels - Online channel GMV growth during the 2024 618 promotion exceeded 60% for Kefu Mei and 100% for Keli Jin, and during the 2024 Double Eleven promotion, growth exceeded 80% and 150%, respectively[25] - Direct sales through DTC online stores generated revenue of RMB 3,587.2 million, a 66.5% increase from 2023, accounting for 64.8% of total revenue in 2024[34] - Revenue from online direct sales on e-commerce platforms reached RMB 377.1 million, up 112.5% year-over-year, representing 6.8% of total revenue in 2024[35] - Offline direct sales revenue was RMB 169.9 million, a 92.0% increase from 2023, making up 3.0% of total revenue in 2024[36] - Sales to distributors amounted to RMB 1,404.6 million, reflecting a 27.3% increase year-over-year, contributing 25.4% to total revenue in 2024[37] Corporate Governance and Management - The company has adopted the corporate governance code as per the Listing Rules Appendix C1 and has complied with all applicable code provisions during the reporting period, except for deviation from code provision C.2.1[150] - The board of directors consists of 4 executive directors and 3 independent non-executive directors, ensuring compliance with the requirement of having at least one independent non-executive director with appropriate professional qualifications or accounting expertise[151] - The company has established four board committees, including the audit committee, nomination committee, remuneration committee, and corporate governance committee[165] - The company has implemented a training program for directors and senior management regarding compliance with Chinese laws and regulations, with a specific training session held in July 2024[188] - The company has established an ESG governance committee to regularly report on ESG-related matters to the board[66] Employee and Shareholder Engagement - The company employed 1,758 full-time staff, with 37.0% in production, 10.6% in R&D, 32.2% in sales and marketing, and 20.2% in general and administrative roles[105] - The company emphasizes effective communication with shareholders through financial reports, annual general meetings, and timely disclosures on its website[196] - The company encourages shareholder participation in meetings and ensures proper notice is given at least 21 days before annual meetings[197] - The company provides communications in both English and Chinese to facilitate shareholder understanding[198] - The company has a dedicated website (www.xajuzi.com) for regular updates and communication with shareholders and investors[199] Social Responsibility and Community Engagement - The company engaged in social responsibility initiatives, donating products valued at over RMB 14 million during various charitable activities[28] - The "Kefumei" brand introduced a bottle recycling program and engaged in various community outreach activities to promote scientific skincare[23] Risk Management - The company faces various operational risks, including changes in the regulatory environment in China, the ability to provide quality products, and competition from other market participants[185] - The company has implemented a risk management and internal control system to address identified risks, which includes policies and procedures deemed suitable for its operations[185] - Financial risks faced by the company include foreign exchange risk, credit risk, and liquidity risk, with the main financial instruments being cash and cash equivalents[187] - The company conducts annual risk factor identification and assessment, reviewing the effectiveness of risk assessment and control measures[186] Dividends and Shareholder Returns - The board proposed a final dividend of RMB 0.6021 per share and a special dividend of RMB 0.5921 per share[6] - The company's undistributed profits available for distribution to shareholders amounted to RMB 4,057 million as of the reporting period end[75]